Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L8 same l7

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search | Clear | Interrupt

Search History

DATE: Wednesday, September 29, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT; PLUR=YES; OP=ADJ			
L11	US-5976567-A.did.	1	L11
L10	US-5976567-A.did.	1	L10
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L9	L8 same l7	43	L9
L8	nucleic acid or plasmid or dna	252175	L8
L7	lipid particles with encapsulated	211	L7
L6	6287591	9	L6
L5	L4 and l2	1	L5
L4	cationic liposome	4098	L4
L3	L2 same l1	0	L3
L2	SALP	271	L2
L1	cationic lipid or cationic amphiphile	7823	L1

END OF SEARCH HISTORY

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L9: Entry 38 of 43 File: EPAB Nov 19, 1998

PUB-NO: WO0009851278A2
DOCUMENT-IDENTIFIER: WO 9851278 A2
TITLE: HIGH EFFICIENCY ENCAPSULATION OF CHARGED THERAPEUTIC AGENTS IN LIPID VESICLES

PUBN-DATE: November 19, 1998

INVENTOR-INFORMATION:

NAME	COUNTRY
SEMPLE, SEAN C	
KLIMUK, SANDRA K	
HARASYM, TROY	
HOPE, MICHAEL J	
ANSELL, STEVEN M	
CULLIS, PIETER	
SCHERRER, PETER	
DEBEYER, DAN	

INT-CL (IPC): A61 K 9/00
EUR-CL (EPC): A61K009/127

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

End of Result Set

Generate Collection Print

L9: Entry 43 of 43 File: DWPI Aug 12, 1999

DERWENT-ACC-NO: 1999-508459
DERWENT-WEEK: 200272

TITLE: Systemic delivery of serum-stable nucleic acid-lipid particles for cancer therapy

Basic Abstract Text (1):
NOVELTY - A serum-stable nucleic acid fully encapsulated within a lipid particle is administered by injection at a site distal to a neoplasia being treated in a mammal.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L9: Entry 36 of 43 File: USPT May 30, 1995

DOCUMENT-IDENTIFIER: US 5419914 A
TITLE: Phospholipid analogue vesicle

Brief Summary Text (11):
The invention comprises a lipid particle including a succinimidyl moiety, preferably in the form of a N-ethylsuccinimidylthiol (NEST) moiety, extending from the surface of the particle in the absence of an extending ligand conjugate. The succinimidyl moiety is attached to a phospholipid molecule to form a succinimidyl phospholipid analogue, preferably in the form of a NEST-lipid entity and most preferably in the form of a N-(N-ethylsuccinimidylthio)phosphatidylethanolamine (NESTPE) moiety, specifically N-(N-ethylsuccinimidylthio) distearoylphosphatidylethanolamine (NEST-DSPE). At least one such phospholipid analogue is included in the outer phospholipid layer of the lipid particle with the succinimidyl moiety extending therefrom, to form a phospholipid analogue particle, which is capable of permitting the encapsulated contents of the lipid particle (e.g., a liposome) to enter the cell cytoplasmically in the essential absence of lysosomal degradation. Active agents which may be encapsulated in the lipid particles of the invention, and delivered intact to the cytoplasm, include lysosomal sensitive therapeutics (such as cytosine arabinosine) proteins and peptides, nucleic acids, oligonucleotides, genes, plasmids and other lysosomal sensitive agents.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L9: Entry 33 of 43 File: USPT Jul 11, 2000

DOCUMENT-IDENTIFIER: US 6086913 A
TITLE: Liposomal delivery of AAV vectors

CLAIMS:

6. The composition of claim 1, wherein the lipid formulation comprises lipids complexed with the vector by

a) combining the vector with cationic lipids in a detergent solution to provide a coated vector-lipid complex;

b) contacting noncationic lipids with the coated vector-lipid complex to provide a solution comprising detergent, a vector-lipid complex and noncationic lipids; and

c) removing the detergent from the solution of step b to provide a solution of serum-stable plasmid-lipid particles, wherein the plasmid is encapsulated in a lipid bilayer and the particles are serum-stable and have a size from about 50-150 nm.

7. The composition of claim 1, wherein the lipid formulation comprises lipids complexed with the vector by

preparing a mixture comprising cationic lipids and noncationic lipids in an organic solvent;

contacting an aqueous solution of said vector with the mixture to provide a clear single phase and

removing the organic solvent to provide a suspension of plasmid-lipid particles, wherein the plasmid is encapsulated in a lipid bilayer, and the particles are stable in serum and have a size of about 50-150 nm.

Previous Doc Next Doc Go to Doc#